Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Fumiyoshi Ishikawa is active.

Publication


Featured researches published by Fumiyoshi Ishikawa.


Biochemical Pharmacology | 1990

Effects of arginine derivatives on soluble guanylate cyclase from neuroblastoma N1E 115 cells.

Masanori Yoshioka; Hiroyuki Fujimoris; Takeo Deguchi; Hiroyuki Masayasu; Kaoru Suzuki; Kazue Inamura; Akira Kosasayama; Fumiyoshi Ishikawa

The effects of L-arginine (Arg) derivatives on soluble guanylate cyclase from neuroblastoma N1E 115 cells were examined. The Arg derivatives were modified at the -NH2, -COOH, C alpha-proton or guanidino group of Arg. Among the synthesized derivatives, eight compounds, i.e. the 5-(dimethylamino)-1-naphthalenesulfonyl (DNS) ones, especially N-cyclohexyl-2-(N-DNSamino)-5-guanidino-2-methylvaleramide and 1-[2-(N-DNSamino)-2-(2-imino-1,2,3,4,5,6-hexahydropyrimidin- 4-yl)acetyl]- piperidine, were found to inhibit the activity of crude guanylate cyclase in the 105,000 g supernatant fraction of the cell homogenate. The enzyme, partially purified by a column of Chelex 100 Na+, was also inhibited by these eight compounds. The mode of the inhibition was competitive. The Ki values were in the range of 2-8 microM for the enzyme in the 105,000 g supernatant fraction and 3-16 microM for the partially purified enzyme, in the presence of Mg2+ as a metal cofactor. In contrast, a new derivative, methyl 2-amino-5-guanidinovalerate (M Arg ME), as well as the Arg methyl ester (Arg ME) and Arg; were found to enhance the activity of the partially purified guanylate cyclase; KA values of M Arg ME, Arg ME and Arg were approximately 9, 4 and 3 microM respectively. From these results, the free guanidino group including 2-imino-1,2,3,4,5,6-hexahydropyrimidin-4-yl or 2-imino-1,2,3,4,5,6-hexahydropyrimidin-5-yl and modification of the --NH2 residue with a hydrophobic group such as DNS seemed to be essential for inhibition of the guanylate cyclase; however, the guanidino and --NH2 residue of Arg should be free for activation by these Arg derivatives.


Chemical & Pharmaceutical Bulletin | 1980

Cyclic Guanidines. X. Synthesis of 2-(2,2-Disubstituted Ethenyl-and Ethyl)-2-imidazolines as Potent Hypoglycemics

Fumiyoshi Ishikawa


Journal of Medicinal Chemistry | 1981

Cyclic guanidines. 14. Imidazo[1,2-a]thienopyrimidin-2-one derivatives as blood platelet aggregation inhibitors.

Fumiyoshi Ishikawa; Akira Kosasayama; Hitoshi Yamaguchi; Yoshifumi Watanabe; Junji Saegusa; Seiichi Shibamura; Kyoko Sakuma; Shin-ichiro Ashida; Yasushi Abiko


Chemical & Pharmaceutical Bulletin | 1980

Cyclic guanidines. IX. Synthesis of 2-amino-3,4-dihydroquinazolines as blood platelet aggregation inhibitors.

Fumiyoshi Ishikawa; Yoshifumi Watanabe; Junji Saegusa


Journal of Medicinal Chemistry | 1989

Thromboxane A2 synthetase inhibitors. 2. Syntheses and activities of tetrahydronaphthalene and indane derivatives

Munefumi Kanao; Yoshifumi Watanabe; Youichi Kimura; Junji Saegusa; Kenjiro Yamamoto; Hideyuki Kanno; Naoaki Kanaya; Hideo Kubo; Shinichiro Ashida; Fumiyoshi Ishikawa


Journal of Medicinal Chemistry | 1985

Cyclic guanidines. 17. Novel (N-substituted amino)imidazo[2,1-b]quinazolin-2 ones: water-soluble platelet aggregation inhibitors.

Fumiyoshi Ishikawa; Junji Saegusa; Kazue Inamura; Kyoko Sakuma; Shinichiro Ashida


Chemical & Pharmaceutical Bulletin | 1978

Cyclic Guanidines. I. Synthesis of Hypoglycemic 1-Substituted 2-Imino-1, 3-diazacycloalkanes

Fumiyoshi Ishikawa; Akira Kosasayama; Shigetake Nakamura


Chemical & Pharmaceutical Bulletin | 1965

Synthesis of 3-pyridinols. I. Reaction of 5-unsubstituted oxazoles with acrylonitrile.

Takeo Naito; Toru Yoshikawa; Fumiyoshi Ishikawa; Sumiro Isoda; Yoshiaki Omura; Isao Takamura


Chemical & Pharmaceutical Bulletin | 1965

Synthesis of 3-Pyridinols. II. Reaction of 4-Methyloxzaole with Dienophiles

Toru Yoshikawa; Fumiyoshi Ishikawa; Yoshiaki Omura; Takeo Naito


Archive | 1979

1,2,3,5-tetrahydroimidazothienopyrimidin-2-ones, a process for their preparation and pharmaceutical compositions

Fumiyoshi Ishikawa; Shinichiro Ashida

Collaboration


Dive into the Fumiyoshi Ishikawa's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Yoshifumi Watanabe

Tokyo Institute of Technology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge